SEC Form 4Coverage since Sep 16, 2025Open-market trades only
$KYMR insider trading
Over the last 12 months, Kymera Therapeutics insiders reported 1 buy totaling $172.5M and 51 sales totaling $471.9M across SEC Form 4 filings. 85% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $172.5M 1 event
- Sold · 12m
- $471.9M 51 events
- Events · 12m
- 52 Form 4 filings, grouped
- Insiders · 12m
- 12 distinct reporters
- 10b5-1 share
- 85% of events, not dollars
Side
Price · $KYMR · 3Mvia TradingView
Top insiders · 12m
Booth Bruce—13× · $217.7M
Mainolfi NelloChief Executive Officer8× · $34.9M
Chadwick Jeremy GChief Operating Officer7× · $14.5M
Goodman NoahChief Business Officer5× · $2.2M
Esposito Pamela—4× · $3.1M
All insider trades
50 of 52 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Adams BrianChief Legal Officer · O | ▼ Sale | 6,371 | $116.83 | $744K | -11.3% | 3 tranches |
| Jul 7, 2026 | Mainolfi NelloChief Executive Officer · O·D | ▼ Sale | 50,000 | $119 | $6.0M | -7% | plan |
| Jul 1, 2026 | Goodman NoahChief Business Officer · O | ▼ Sale | 3,389 | $114.29 | $387K | -6.7% | plan |
| Jul 1, 2026 | Mainolfi NelloChief Executive Officer · O·D | ▼ Sale | 80,000 | $115.29 | $9.2M | -10.7% | plan · 5 tranches |
| Jun 30, 2026 | Jacobs Bruce N.Chief Financial Officer · O | ▼ Sale | 77,109 | $114.96 | $8.9M | -23.9% | plan · 8 tranches |
| Jun 29, 2026 | Booth BruceD | ▼ Sale | 31,283 | $109.48 | $3.4M | -6.3% | plan · 8 tranches · indirect |
| Jun 29, 2026 | Booth BruceD | ▼ Sale | 513,245 | $110.01 | $56.5M | -52.4% | plan · 30 tranches · indirect |
| Jun 26, 2026 | BVF PARTNERS L P/ILD | ▼ Sale | 51,858 | $106.5 | $5.5M | -39.7% | indirect |
| Jun 26, 2026 | BVF PARTNERS L P/ILD | ▼ Sale | 1,578,800 | $106.5 | $168.1M | -86.8% | 3 tranches |
| Jun 25, 2026 | Booth BruceD | ▼ Sale | 285,684 | $121.86 | $34.8M | -35% | plan · 22 tranches · indirect |
| Jun 25, 2026 | Booth BruceD | ▼ Sale | 398,765 | $110.31 | $44.0M | -41.4% | plan · 30 tranches · indirect |
| Jun 25, 2026 | Goodman NoahChief Business Officer · O | ▼ Sale | 5,000 | $114 | $570K | -9.1% | plan · 2 tranches |
| Jun 22, 2026 | Booth BruceD | ▼ Sale | 31,798 | $103.75 | $3.3M | -4.9% | plan · 4 tranches · indirect |
| Jun 22, 2026 | Booth BruceD | ▼ Sale | 466,457 | $94.84 | $44.2M | -43% | plan · 28 tranches · indirect |
| Jun 22, 2026 | Goodman NoahChief Business Officer · O | ▼ Sale | 2,500 | $99 | $248K | -4.7% | plan |
| Jun 17, 2026 | Booth BruceD | ▼ Sale | 11,741 | $89.98 | $1.1M | -100% | plan |
| May 26, 2026 | Chadwick Jeremy GChief Operating Officer · O | ▼ Sale | 3,730 | $78.36 | $292K | -6.1% | plan |
| May 11, 2026 | Ridloff ElenaD | ▼ Sale | 3,000 | $87 | $261K | -100% | plan |
| Apr 29, 2026 | Mainolfi NelloChief Executive Officer · O·D | ▼ Sale | 30,000 | $81.18 | $2.4M | -4.3% | plan · 3 tranches |
| Apr 22, 2026 | Booth BruceD | ▼ Sale | 100 | $90.08 | $9K | — | plan · 2 tranches · indirect |
| Apr 22, 2026 | Booth BruceD | ▼ Sale | 5,900 | $89.96 | $531K | -100% | plan |
| Apr 22, 2026 | Chadwick Jeremy GChief Operating Officer · O | ▼ Sale | 300 | $90 | $27K | -0.5% | plan |
| Apr 15, 2026 | Booth BruceD | ▼ Sale | 3,135 | $90.1 | $282K | -0.5% | plan · 2 tranches · indirect |
| Apr 15, 2026 | Booth BruceD | ▼ Sale | 6,359 | $89.96 | $572K | -100% | plan · 2 tranches |
| Apr 15, 2026 | Chadwick Jeremy GChief Operating Officer · O | ▼ Sale | 6,551 | $90 | $590K | -9.7% | plan · 2 tranches |
| Apr 14, 2026 | Goodman NoahChief Business Officer · O | ▼ Sale | 1,347 | $90 | $121K | -2.6% | plan |
| Apr 10, 2026 | Goodman NoahChief Business Officer · O | ▼ Sale | 10,264 | $87.47 | $898K | -16.6% | plan · 4 tranches |
| Apr 1, 2026 | Ridloff ElenaD | ▼ Sale | 12,000 | $85.39 | $1.0M | -100% | plan · 3 tranches |
| Apr 1, 2026 | Chadwick Jeremy GChief Operating Officer · O | ▼ Sale | 22,240 | $85.43 | $1.9M | -26.7% | plan · 3 tranches |
| Mar 25, 2026 | Chadwick Jeremy GChief Operating Officer · O | ▼ Sale | 115,977 | $78.02 | $9.0M | -65.5% | plan · 6 tranches |
| Mar 20, 2026 | Esposito PamelaD | ▼ Sale | 2,500 | $79.15 | $198K | -100% | plan · 3 tranches |
| Mar 11, 2026 | Chadwick Jeremy GChief Operating Officer · O | ▼ Sale | 25,758 | $83.3 | $2.1M | -27.5% | plan · 3 tranches |
| Mar 4, 2026 | Chadwick Jeremy GChief Operating Officer · O | ▼ Sale | 5,958 | $86.54 | $516K | -7.5% | 7 tranches |
| Mar 4, 2026 | Gollob JaredChief Medical Officer · O | ▼ Sale | 10,508 | $87.24 | $917K | -8.2% | 7 tranches |
| Mar 4, 2026 | Jacobs Bruce N.Chief Financial Officer · O | ▼ Sale | 12,471 | $87.5 | $1.1M | -5.1% | 7 tranches |
| Mar 2, 2026 | Booth BruceD | ▼ Sale | 81,866 | $90.13 | $7.4M | -10.8% | plan · 2 tranches · indirect |
| Feb 25, 2026 | Mainolfi NelloChief Executive Officer · O·D | ▼ Sale | 30,000 | $90.26 | $2.7M | -4.3% | plan · 5 tranches |
| Feb 20, 2026 | Esposito PamelaD | ▼ Sale | 2,500 | $87.31 | $218K | -100% | plan · 2 tranches |
| Jan 20, 2026 | Esposito PamelaD | ▼ Sale | 5,500 | $67.91 | $374K | -100% | plan · 3 tranches |
| Dec 31, 2025 | Mainolfi NelloChief Executive Officer · O·D | ▼ Sale | 30,000 | $78.06 | $2.3M | -4.3% | plan · 2 tranches |
| Dec 17, 2025 | Esposito PamelaD | ▼ Sale | 27,563 | $82.16 | $2.3M | -100% | plan · 4 tranches |
| Dec 12, 2025 | Booth BruceD | ▼ Sale | 236,588 | $91.72 | $21.7M | -25.7% | 14 tranches · indirect |
| Dec 11, 2025 | BAKER BROS. ADVISORS LPD·10% | ▲ Buy | 2,005,813 | $86 | $172.5M | +33.7% | 2 tranches · indirect |
| Dec 8, 2025 | Albers Jeffrey W.D | ▼ Sale | 5,000 | $89.76 | $449K | -100% | plan · 2 tranches |
| Dec 8, 2025 | Mainolfi NelloChief Executive Officer · O·D | ▼ Sale | 100,000 | $89.17 | $8.9M | -13.1% | plan |
| Dec 8, 2025 | Gollob JaredChief Medical Officer · O | ▼ Sale | 49,307 | $88.67 | $4.4M | -31% | plan · 6 tranches |
| Oct 29, 2025 | Mainolfi NelloChief Executive Officer · O·D | ▼ Sale | 30,000 | $60.99 | $1.8M | -4.3% | plan · 3 tranches |
| Oct 15, 2025 | Gollob JaredChief Medical Officer · O | ▼ Sale | 59,576 | $61.42 | $3.7M | -35.1% | plan · 4 tranches |
| Oct 13, 2025 | Gollob JaredChief Medical Officer · O | ▼ Sale | 3,114 | $60 | $187K | -2.6% | plan |
| Oct 13, 2025 | Albers Jeffrey W.D | ▼ Sale | 5,000 | $59.19 | $296K | -100% | plan |
Every $KYMR filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Kymera Therapeutics filings can reach your inbox instead.
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $KYMR feed.